These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer. Zhang J, Qu Z, Yao H, Sun L, Harata-Lee Y, Cui J, Aung TN, Liu X, You R, Wang W, Hai L, Adelson DL, Lin L. Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954 [Abstract] [Full Text] [Related]
25. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H, Xu L. Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264 [Abstract] [Full Text] [Related]
26. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, Ai B, Cao X, Guo T, Liao Y. J Exp Clin Cancer Res; 2019 Mar 15; 38(1):129. PubMed ID: 30876460 [Abstract] [Full Text] [Related]
27. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K. Mol Cancer Ther; 2010 Jun 15; 9(6):1647-56. PubMed ID: 20530710 [Abstract] [Full Text] [Related]
28. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells. Zhao XM, Pan SY, Huang QL, Lu YN, Wu XH, Chang JH, Liu ZB, Cai XW, Liu Q, Wang JL, Fu XL. Oncotarget; 2016 Aug 02; 7(31):49384-49396. PubMed ID: 27283902 [Abstract] [Full Text] [Related]
29. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib. Zheng F, Zhao Y, Li X, Tang Q, Wu J, Wu W, Hann SS. J Ethnopharmacol; 2019 Jul 15; 239():111928. PubMed ID: 31077779 [Abstract] [Full Text] [Related]
30. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Han SY, Zhao W, Sun H, Zhou N, Zhou F, An G, Li PP. Phytomedicine; 2015 May 15; 22(5):560-7. PubMed ID: 25981922 [Abstract] [Full Text] [Related]
31. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S. Cancer Sci; 2018 Oct 15; 109(10):3183-3196. PubMed ID: 30098066 [Abstract] [Full Text] [Related]
32. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression. Li L, Wang S, Zheng F, Wu W, Hann SS. J Ethnopharmacol; 2016 Dec 24; 194():918-929. PubMed ID: 27989877 [Abstract] [Full Text] [Related]
33. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G. Lung Cancer; 2014 Feb 24; 83(2):146-53. PubMed ID: 24331411 [Abstract] [Full Text] [Related]
34. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Oh HN, Lee MH, Kim E, Yoon G, Chae JI, Shim JH. Phytomedicine; 2019 Oct 24; 63():153014. PubMed ID: 31323446 [Abstract] [Full Text] [Related]
35. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. Wang L, Liu J, Liu J, Chen X, Chang M, Li J, Zhou J, Bai C, Song Y. J Cancer Res Clin Oncol; 2019 Apr 24; 145(4):861-872. PubMed ID: 30661098 [Abstract] [Full Text] [Related]
36. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer. Liu P, Xiang Y, Liu X, Zhang T, Yang R, Chen S, Xu L, Yu Q, Zhao H, Zhang L, Liu Y, Si Y. Molecules; 2019 Feb 12; 24(3):. PubMed ID: 30759826 [Abstract] [Full Text] [Related]
37. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Zhu X, Jiang H, Li J, Xu J, Fei Z. Med Sci Monit; 2016 Apr 29; 22():1435-41. PubMed ID: 27125283 [Abstract] [Full Text] [Related]
38. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer. Feng W, Xie Q, Liu S, Ji Y, Li C, Wang C, Jin L. Cancer Sci; 2018 Jun 29; 109(6):1775-1786. PubMed ID: 29624806 [Abstract] [Full Text] [Related]
39. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. Ge P, Cao L, Chen X, Jing R, Yue W. BMC Cancer; 2019 Dec 10; 19(1):1203. PubMed ID: 31823748 [Abstract] [Full Text] [Related]
40. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Xie M, He CS, Wei SH, Zhang L. Eur J Cancer; 2013 Nov 10; 49(16):3559-72. PubMed ID: 23916913 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]